Grad Cosmin, Pop Andrei, Gaborean Emil, Grad Simona, Dumitrascu Dan
Second Medical Department, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
Exp Ther Med. 2021 Nov;22(5):1347. doi: 10.3892/etm.2021.10782. Epub 2021 Sep 22.
Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), considered as precursor of the intestinal type of gastric cancer, is of growing interest. The combination of pepsinogen (PG), gastrin-17 (G17) and anti- () antibody serological assays (panel test) is a non-invasive tool for the diagnosis of atrophic gastritis. However, the diagnostic reliability of this test remains uncertain. The aim of our study was to assess the diagnostic performance of the serum panel test (GastroPanel) for the diagnosis of atrophic gastritis. From dyspeptic patients, endoscopic biopsy samples (two from the gastric corpus and two from the antrum) and blood samples were collected. The determination of sPGI, sPGII, sG17 and IgG antibodies to (H.p IgG) was performed using an enzyme-linked immunosorbent assay (GastroPanel; Biohit Oyj). Histopathology results were compared with GastroPanel values. Sixty patients were included: 35 (58.3%) females and 25 (41.66%) males; mean age 67.63±9.36 years; 45% -positive. A total of 65% of patients had atrophic gastritis. There were no significant differences between the levels of biomarkers and localization of atrophy. The ratio PG1/PG2 was lower in patients with multifocal atrophy; the difference being close to the threshold of statistical significance. In cases of intestinal metaplasia the values of G17, PG1, PG2, H.p IgG were not statistically altered compared to those without intestinal metaplasia; only the ratio PG1/PG2 was lower in intestinal metaplasia; the difference being almost of statistical significance. Our results revealed that, GastroPanel values did not differ depending on the severity of the atrophy. Biomarkers used by GastroPanel do not have enough accuracy for use in the diagnosis of atrophy in the population studied. A low accuracy only for the ratio PG1/PG2 in patients with multifocal atrophy was found. However, our data revealed a correlation in detecting intestinal metaplasia.
作为肠型胃癌前体的萎缩性胃炎（AG）的血清生物标志物分析日益受到关注。胃蛋白酶原（PG）、胃泌素 - 17（G17）和抗（）抗体血清学检测（组合检测）相结合是诊断萎缩性胃炎的一种非侵入性工具。然而，该检测的诊断可靠性仍不确定。我们研究的目的是评估血清组合检测（胃功能检测组合）对萎缩性胃炎的诊断性能。从消化不良患者中收集内镜活检样本（胃体部两份和胃窦部两份）和血液样本。使用酶联免疫吸附测定法（胃功能检测组合；百得欧亿杰公司）测定血清胃蛋白酶原I（sPGI）、血清胃蛋白酶原II（sPGII）、sG17和抗（幽门螺杆菌IgG）IgG抗体。将组织病理学结果与胃功能检测组合的值进行比较。纳入60例患者：女性35例（58.3%），男性25例（41.66%）；平均年龄67.63±9.36岁；45%为阳性。共有65%的患者患有萎缩性胃炎。生物标志物水平与萎缩部位之间无显著差异。多灶性萎缩患者的PG1/PG2比值较低；差异接近统计学意义阈值。在肠化生病例中，与无肠化生的病例相比，G17、PG1、PG2、幽门螺杆菌IgG的值无统计学改变；仅肠化生时PG1/PG2比值较低；差异几乎具有统计学意义。我们的结果显示，胃功能检测组合的值不因萎缩严重程度而异。胃功能检测组合所使用的生物标志物在本研究人群中用于萎缩诊断的准确性不足。仅发现多灶性萎缩患者的PG1/PG2比值准确性较低。然而，我们的数据显示在检测肠化生方面存在相关性。
